Squamous cell carcinoma and precursor lesions: Prevention

Periodontology 2000

Volumn 57, Issue 1, 2011, Pages 38-50

  Warnakulasuriya, Saman ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CHEMOPROPHYLAXIS; DRINKING BEHAVIOR; HUMAN; MASS SCREENING; MOUTH TUMOR; PRECANCER; SMOKING CESSATION; SQUAMOUS CELL CARCINOMA;

ALCOHOL DRINKING; ANTICARCINOGENIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOPREVENTION; HUMANS; MASS SCREENING; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; TOBACCO USE CESSATION;

EID: 79960629582     PISSN: 09066713     EISSN: 16000757     Source Type: Journal    
DOI: 10.1111/j.1600-0757.2011.00395.x     Document Type: Article

References (121)

1. Arduino PG, Surace A, Carbone M, Elia A, Massolini G, Gandolfo S, Broccoletti R. Outcome of oral dysplasia: a retrospective hospital-based study of 207 patients with a long follow-up. J Oral Pathol Med 2009: 38: 540-544.
2. Bala M, Strzeszynski L, Cahill K. Mass media interventions for smoking cessation in adults. Cochrane Database Syst Rev 2008: (e-publication only).
3. Banoczy J, Csiba A. Occurrence of epithelial dysplasia in oral dysplasia. Oral Surg Oral Med Oral Pathol 1976: 42: 766-773.
4. Benner SE, Winn RJ, Lippman SM, Poland J, Hansen KS, Luna MA, Hong WK. Regression of oral leukoplakia with α-tocopherol: a community Clinical Oncology Program (CCOP) chemoprevention study. J Natl Cancer Inst 1993: 85: 44-47.
5. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol 2006: 7: 149-156.
6. Bosetti C, Gallus S, Peto R, Negri E, Talamini R, Tavani A, Franceschi S, La Vecchia C. Tobacco smoking, smoking cessation, and cumulative risk of upper aerodigestive tract cancers. Am J Epidemiol 2008: 167: 468-473.
7. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007: (e-publication only).
8. Chen HM, Yu CH, Tu PC, Yeh CY, Tsai T, Chiang CP. Successful treatment of oral verrucous hyperplasia and oral leukoplakia with topical 5-aminolevulinic acid-mediated photodynamic therapy. Lasers Surg Med 2005: 37: 114-122.
9. Chiesa F, Tradati N, Grigolato R, Boracchi P, Biganzoli E, Crose N, Cavadini E, Formelli F, Costa L, Giardini R, Zurrida S, Costa A, De Palo G, Veronesi U. Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer 2005: 115: 625-629.
10. Coredero AA, Allevato MAJ, Barclay CA. Treatment of lichen planus and leukoplakia with oral retinoid Ro 10-0359. In: Orfanos CE, Braun-Falco O, Farber EM, Grupper C, Polano MK, Schuppli R, editors. Retinoids: advances in basic research and therapy. Berlin: Springer, 1981: 273-278.
11. Cowan CG, Gregg TA, Napier SS, Mckenna SM, Kee F. Potentially malignant oral lesions in Northern Ireland: a 20-year population-based perspective of malignant transformation. Oral Dis 2001: 7: 18-24.
12. Croucher R, Islam S, Jarvis MJ, Garrett M, Rahman R, Shajahan S, Howells G. Oral tobacco cessation with UK resident Bangladeshi women: a community pilot investigation. Health Educ Res 2003: 18: 216-223.
13. Ebbert JO, Montori V, Erwin PC, Stead LF. Interventions for smokeless tobacco use cessation. Cochrane Database Syst Rev 2011: (e-publication only).
14. Eisenberg MJ, Filion KB, Yavin D, Bélisle P, Mottillo S, Joseph L, Gervais A, O'Loughlin J, Paradis G, Rinfret S, Pilote L. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. Can Med Assoc J 2008: 179: 135-144.
15. Elamin F, Steingrimsdottir H, Warnakulasuriya S, Johnson N, Tavassoli M. Prevalence of human papillomavirus infection in premalignant and malignant lesions of the oral cavity in UK subjects. A novel method of detection. Oral Oncol 1998: 34: 191-197.
16. Epstein JB, Gorosky M, Wong FLW, Millner A. Topical bleomycin for the treatment of dysplastic oral leukoplakia. Cancer 1998: 83: 628-634.
17. Epstein JB, Gorsky M. Topical application of vitamin A to oral leukoplakia. Cancer 1999: 86: 921-927.
18. Fan KF, Hopper C, Speight PM, Buonaccorsi G, MacRobert AJ, Brown SG. Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer 1996: 78: 1374-1383.
19. Fedele S. Diagnostic aids in screening of oral cancer. Head Neck Oncol 2009: 1: 5-11.
20. Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P, Boyle P. Tobacco smoking and cancer: a meta-analysis. Int J Cancer 2008: 122: 155-164.
21. Garewal HS, Katz RV, Meyskens F, Pitcock J, Morse D, Friedman S, Peng Y, Pendrys DG, Mayne S, Alberts D, Kiersch T, Graver E. β-carotene produces sustained remissions in patients with oral leukoplakia: results of a multicentre prospective trial. Arch Otolaryngol Head Neck Surg 1999: 125: 1305-1310.
22. Garewal HS, Mayskens FL, Killen D, Reeves D, Kiersch TA, Elletson H, Strosberg A, King D, Steinbronn K. Response of oral leukoplakia to beta-carotene. J Clin Oncol 1990: 8: 1715-1720.
23. Gillison ML. Current topics in the epidemiology of oral cavity and oropharyngeal cancers. Head Neck 2007: 29: 779-792.
24. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004: (e-publication only).
25. Gupta PC, Mehta FS, Daftary DK, Pindborg JJ, Bhonsle RB, Jalnawalla PN, Sinor PN, Pitkar VK, Murti PR, Irani RR, Shah HT, Kadam PM, Iyer KS, Iyer HM, Hegde AK, Chandrashekar GK, Shiroff BC, Sahiar BE, Mehta MN. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol 1980: 8: 287-333.
26. Gupta PC, Mehta FS, Pindborg JJ, Bhonsle RB, Murti PR, Daftary DK, Aghi MB. Primary prevention trial of oral cancer in India: a 10-year follow- up study. J Oral Pathol Med 1992: 21: 433-439.
27. Gupta PC, Murti PR, Bhonsle RB, Mehta FS, Pindborg JJ. Effect of cessation of tobacco use on the incidence of oral mucosal lesions in a 10-yr follow-up study of 12, 212 users. Oral Dis 1995: 1: 54-58.
28. Gupta PC, Warnakulasuriya S. Global epidemiology of areca nut use. Addict Biol 2002: 7: 77-83.
29. Hammersley N, Ferguson MM, Rennie JS. Topical bleomycin in the treatment of oral leukoplakia: a pilot study. Br J Oral Maxillofac Surg 1985: 23: 251-258.
30. Hashibe M, Sankaranarayanan R, Thomas G, Kuruvilla B, Mathew B, Somanathan T, Parkin DM, Zhang ZF. Alcohol drinking, body mass index and the risk of oral leukoplakia in an Indian population. Int J Cancer 2000: 88: 129-134.
31. Hogewind WFC, van der Kwast WAM, van der Waal I. Oral leukoplakia, with emphasis on malignant transformation. J Craniomaxillofac Surg 1989: 17: 128-133.
32. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. Oral Oncol 2006: 42: 461-474.
33. Holmstrup P. Can we prevent malignancy by treating premalignant lesions? Oral Oncol 2009: 45: 549-550.
34. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, Fofonoff S, Byers R, Atkinson EN, Vaughan C, Toth BB, Kramer A, Dimery IW, Skipper P, Strong S. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986: 315: 1501-1505.
35. Hsue SS, Wang WC, Chen CH, Lin CC, Chen YK, Lin LM. Malignant transformation in 1458 patients with potentially malignant oral mucosal disorders: a follow-up study based in a Taiwanese hospital. J Oral Pathol Med 2007: 36: 25-29.
36. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2006: (e-publication only).
37. International Agency on Research for Cancer. IARC monographs on the evaluation of carcinogenic risks to humans, Volume 96: alcohol consumption and ethyl carbamate. Lyon, France: IARC Press, 2010.
38. International Agency on Research for Cancer. IARC monographs on the evaluation of carcinogenic risks to humans, Volume 85: betel-quid and areca-nut chewing and some areca-nut-derived nitrosamines. Lyon, France: IARC Press, 2004.
39. Jacob BJ, Straif K, Thomas G, Ramadas K, Mathew B, Zhang ZF, Sankaranarayanan R, Hashibe M. Betel quid without tobacco as a risk factor for oral precancers. Oral Oncol 2004: 40: 697-704.
40. Johnson NW, Jayasekara P, Amarasinghe AAHK. Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology. Periodontol 2000 2011: 57: 19-37.
41. Kaugars GE, Silverman S, Lovas JGL, Brandt RB, Riley WT, Dao Q, Singh VN, Gallo J. A clinical trial of antioxidant supplements in the treatment of oral leukoplakia. Oral Surg Oral Med Oral Pathol 1994: 78: 462-468.
42. Kerr AR, Warnakulasuriya S, Mighell A, Dietrich T, Nasser M, Rimal J, Jalil A, Bornstein MM, Nagao T, Fortune F, Hazarey VH, Reichart PA, Silverman S, Johnson NW. Management issues in oral submucous fibrosis: a systematic review of medical interventions and recommendations for future research. Oral Dis 2011: 17(Suppl. 1): 42-57.
43. Koch HF. Effects of retinoids on precancerous lesions of oral mucosa. In: Orfanos CE, Braun-Falco O, Farber EM, Grupper C, Polano MK, Schuppli R editors. Retinoids: advances in basic research and therapy. Berlin: Springer, 1981: 307-312.
44. Koch HF. Biochemical treatment of precancerous oral lesions; the effectiveness of various analogues of retinoic acid. J Maxillofac Surg 1978: 6: 59-63.
45. Konopka K, Goslinski T. Photodynamic therapy in dentistry. J Dent Res 2007: 86: 694-707.
46. Kubler AC. Photodynamic therapy. Med Laser Appl 2005: 20: 37-45.
47. Kübler A, Haase T, Rheinwald M, Barth T, Mühling J. Treatment of oral leukoplakia by topical application of 5-aminolevulinic acid. Int J Oral Maxillofac Surg 1998: 27: 466-469.
48. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005: (e-publication only).
49. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, Benner SE, Xu XC, Lee JS, Papadimitrakopoulou VM, Geyer C, Perez C, Martin JW, El-Naggar AK, Lippman SM. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000: 6: 1702-1710.
50. Liede K, Hietanen J, Saxen L, Haukka J, Timonen T, Häyrinen-Immonen R, Heinonen OP. Long-term supplementation with alpha-tocopherol and beta-carotene and prevalence of oral mucosal lesions in smokers. Oral Dis 1998: 4: 78-83.
51. Lind PO. Malignant transformation in oral leukoplakia. Scand J Dent Res 1987: 95: 449-455.
52. Lingen MW, Kalmar JR, Karrison T, Speight PM. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol 2008: 44: 10-22.
53. Lingford-Hughes A, Watson B, Kalk N, Reid A. Neuro-pharmacology of addiction and how it informs treatment. Br Med Bull 2010: 96: 93-110.
54. Lippman SM, Lee JS, Lotan R, Hittleman WN, Wargovich MJ, Hong WK. Biomarkers as intermediate endpoints in chemoprevention trials. J Natl Cancer Inst 1990: 82: 555-560.
55. Lippman SM, Lee JS, Martin JW, El-Naggar AK, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA, Zhou X, Papadimitrakopoulou V, Khuri FR, Tran H, Clayman GL, Hittleman WN, Hong WK, Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res 2006: 12: 3109-3114.
56. Lippmann SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW, Hays GL, Goepfret H, Hong WK. Comparison of low-dose isoretinoin with beta-carotene to prevent oral carcinogenesis. N Engl J Med 1993: 328: 15-20.
57. Lodi G, Porter S. Management of potentially malignant disorders; evidence and critique. J Oral Pathol Med 2008: 37: 63-69.
58. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Interventions for treating oral leukoplakia. Cochrane Database Syst Rev 2004: (e-publication only).
59. Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Radiol Endod 1995: 79: 321-329.
60. Malaker K, Anderson BJ, Beecroft WA, Hodson DI. Management of oral mucosa dysplasia with beta-carotene or retinoic acid: a pilot cross-over study. Cancer Detect Prev 1991: 15: 335-340.
61. Marron M, Boffetta P, Zhang ZF, Zaridze D, Wünsch-Filho V, Winn DM, Wei Q, Talamini R, Szeszenia-Dabrowska N, Sturgis EM, Smith E, Schwartz SM, Rudnai P, Purdue MP, Olshan AF, Eluf-Neto J, Muscat J, Morgenstern H, Menezes A, McClean M, Matos E, Mates IN, Lissowska J, Levi F, Lazarus P, La Vecchia C, Koifman S, Kelsey K, Herrero R, Hayes RB, Franceschi S, Fernandez L, Fabianova E, Daudt AW, Dal Maso L, Curado MP, Cadoni G, Chen C, Castellsague X, Boccia S, Benhamou S, Ferro G, Berthiller J, Brennan P, Møller H, Hashibe M. Cessation of alcohol drinking, tobacco smoking and reversal of head and neck cancer risk. Int J Epidemiol 2010: 39: 182-196.
62. Mehanna HM, Rattay T, Smith J, McConkey CC. Treatment and follow-up of oral dysplasia - a systematic review and meta-analysis. Head Neck 2009: 31: 1600-1609.
63. Mincer HH, Coleman SA, Hopkins KP. Observations on the clinical characteristics of oral lesions showing histologic epithelial dysplasia. Oral Surg Oral Med Oral Pathol 1972: 33: 389-399.
64. Morse DE, Katz RV, Pendrys DG, Holford TR, Krutchkoff DJ, Eisenberg E, Kosis D, Mayne ST. Smoking and drinking in relation to oral epithelial dysplasia. Cancer Epidemiol Biomarkers Prev 1996: 5: 769-777.
65. Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, Martin JW, Steinberg SM, Liewehr DJ, Avis I, Linnoila RI, Hewitt S, Lippman SM, Frye R, Cavanaugh PF Jr. Randomized, double-blind, placebo controlled phaseIIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 2004: 10: 1565-1573.
66. Nagao T, Warnakulasuriya S, Ito Y, Fukano H, Yuassa H, Nakamura T, Yamamoto K, Uchida K, Kato S, Shimozato K. Beta-carotene and vitamin C supplements for oral leukoplakia. In: Mouth and Medicine - 7th Biennial Congress of the European Association of Oral Medicine. Berlin: European Association of Oral Medicine, 2004: Abst. 33.
67. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med 2008: 37: 1-10.
68. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002: 8: 314-346.
69. Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CA, Helman JI, Du B, Yueh B, Boyle JO. Pilot randomized phaseII study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008: 14: 2095-2101.
70. Parker AJR, Marshall EJ, Ball DM. Diagnosis and management of alcohol use disorders. Br Med J 2008: 336: 496-501.
71. Pavia M, Pileggi C, Nobile CG, Angelilo F. Association between fruit and vegetable consumption and oral cancer; a meta-analysis of observational studies. Am J Clin Nutr 2006: 83: 1126-1134.
72. Petersen PE. Strengthening the prevention of oral cancer; the WHO perspective. Community Dent Oral Epidemiol 2005: 33: 397-399.
73. Piattelli A, Fioroni M, Santinelli A, Rubini C. bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study. Oral Oncol 1999: 35: 314-320.
74. Poate TWJ, Warnakulasuriya KAAS. Effective management of smoking in an oral dysplastic clinic in London. Oral Dis 2006: 12: 22-26.
75. Ramseier CA, Warnakulasuriya S, Needleman IG, Gallagher JE, Lahtinen A, Ainamo A, Alajbeg I, Albert D, Al-Hazmi N, Antohé ME, Beck-Mannagetta J, Benzian H, Bergström J, Binnie V, Bornstein M, Büchler S, Carr A, Carrassi A, Casals Peidró E, Chapple I, Compton S, Crail J, Crews K, Davis JM, Dietrich T, Enmark B, Fine J, Gallagher J, Jenner T, Forna D, Fundak A, Gyenes M, Hovius M, Jacobs A, Kinnunen T, Knevel R, Koerber A, Labella R, Lulic M, Mattheos N, McEwen A, Ohrn K, Polychronopoulou A, Preshaw P, Radley N, Rosseel J, Schoonheim-Klein M, Suvan J, Ulbricht S, Verstappen P, Walter C, Warnakulasuriya S, Wennström J, Wickholm S, Zoitopoulos L. Consensus report: 2nd European Workshop on Tobacco Use Prevention and Cessation for Oral Health Professionals. Int Dent J 2010: 60: 3-6.
76. Ribeiro AS, Salles PR, da Silva TA, Mesquita RA. A review of the nonsurgical treatment of oral leukoplakia. Int J Dent 2010: 2010: 186018 published online doi:.
77. Rice VH, Stead LF. Nursing interventions for smoking cessation. Cochrane Database Syst Rev 2007: (e-publication only).
78. Roed-Petersen B. Effect on oral leukoplakia of reducing or ceasing tobacco smoking. Acta Derm Venereol 1982: 62: 164-167.
79. Saito T, Sugiura C, Hirai A, Notani K, Totsuka Y, Shindoh M, Fukuda H. Development of squamous cell carcinoma from pre-existent oral leukoplakia: with respect to treatment modality. Int J Oral Maxillofac Surg 2001: 30: 49-53.
80. Sankaranarayanan R, Mathew B, Varghese C, Sudhakaran PR, Menon V, Jayadeep A, Nair MK, Mathews C, Mahalingam TR, Balaram P, Nair PP. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncol 1997: 33: 231-236.
81. Sankaranarayanan R, Ramadas K, Thomas G, Muwonge R, Thara S, Mathew B, Rajan B, Trivandrum Oral Cancer Screening Study Group. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet 2005: 365: 1927-1933.
82. Scheer M, Kuebler AC, Zoller JE. Chemoprevention of oral squamous cell carcinomas. Onkologie 2004: 27: 187-193.
83. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from the Netherlands. Oral Oncol 1998: 34: 270-275.
84. Sellman JD, Sullivan PF, Dore GM, Adamson SJ, MacEwan I. A randomized controlled trial of motivational enhancement therapy (MET) for mild to moderate alcohol dependence. J Stud Alcohol 2001: 62: 389-396.
85. Shah JP, Strong EW, DeCosse J, Itri L, Sellers P. Effect of retinoids on oral leukoplakia. Am J Surg 1983: 146: 466-470.
86. Shiu MN, Chen TH. Impact of betel quid, tobacco and alcohol on three-stage disease natural history of oral leukoplakia and cancer: implications for prevention of cancer. Eur J Cancer Prev 2004: 13: 39-45.
87. Sieroń A, Adamek M, Kawczyk-Krupka A, Mazur S, Ilewicz L. Photodynamic therapy (PDT) using topically applied δ-aminolevulinic acid (ALA) for the treatment of oral leukoplakia. J Oral Pathol Med 2003: 32: 330-336.
88. Silverman S, Bhargava K, Mani NJ, Smith LW, Malaowalla AM. Malignant transformation and natural history of oral leukoplakia in 57, 518 industrial workers of Gujarat, India. Cancer 1976: 38: 1790-1795.
89. Silverman S, Renstrup G, Pindborg JJ. Studies in oral leukoplakias: III. Effects of vitaminA comparing clinical, histopathological, cytologic, and haematologic responses. Acta Odontol Scand 1963: 21: 271-292.
90. Silverman S, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984: 53: 563-568.
91. Singh M, Krishanappa R, Bagewadi A, Keluskar V. Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncol 2004: 40: 591-596.
92. Smith SE, Warnakulasuriya KA, Feyerabend C, Belcher M, Cooper DJ, Johnson NW. A smoking cessation programme conducted through dental practices in the UK. Br Dent J 1998: 185: 299-303.
93. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev 2008: (e-publication only).
94. Stead lF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2007: (e-publication only).
95. Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK. Response of oral leukoplakia with vitaminA. Cancer Lett 1988: 40: 93-100.
96. Stich HF, Rosin MP, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK. Remission of oral leukoplakia and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitaminA. Int J Cancer 1988: 42: 195-199.
97. Sugar L, Banoczy J. Follow-up studies in oral leukoplakia. Bull World Health Organ 1969: 41: 289-293.
98. Thomas S, Fayter D, Misso K, Ogilvie D, Petticrew M, Sowden A, Whitehead M, Worthy G. Population tobacco control interventions and their effects on social inequalities in smoking: systematic review. Tob Control 2008: 17: 230-237.
99. Thomas SJ, Harris R, Ness AR, Taulo J, Maclennan R, Howes N, Bain CJ. Betel quid not containing tobacco and oral leukoplakia; a report on a cross-sectional study in Papua New Guinea and a meta-analysis of current evidence. Int J Cancer 2008: 123: 1871-1876.
100. Toma S, Benso S, Albanese E, Palumbo R, Cantoni E, Nicolò G, Mangiante P. Treatment of oral leukoplakia with beta-carotene. Oncology 1992: 49: 77-81.
101. Toma S, Mangiante PE, Margarino G, Nicolo G, Palumbo R. Progressive 13-cis-retinoid acid dosage in the treatment of oral leukoplakia. Oral Oncol 1992: 28: 121-123.
102. Tsai JC, Chiang CP, Chen HM, Huang SB, Wang CW, Lee MI, Hsu YC, Chen CT, Tsai T. Photodynamic therapy of oral dysplasia with topical 5-aminolevulinic acid and light-emitting diode array. Lasers Surg Med 2004: 34: 18-24.
103. 2 laser surgery in patients with oral leukoplakia: a 25 year follow up. Oral Oncol 2005: 41: 31-37.
104. Vedtofte P, Holmstrup P, Hjorting-Hansen E, Pindborg JJ. Surgical treatment of premalignant lesions of the oral mucosa. Int J Oral Maxillofac Surg 1987: 16: 656-664.
105. Warnakulasuriya S, Cain N. Screening for oral cancer: contributing to the debate. J Invest Clin Dent 2011: 2: 2-9.
106. Warnakulasuriya S, Dietrich T, Bornstein MM, Casals Peidró E, Preshaw PM, Walter C, Wennström JL, Bergström J. Oral health risks of tobacco use and effects of cessation. Int Dent J 2010: 60: 7-30.
107. Warnakulasuriya S. Causes of oral cancer - an appraisal of controversies. Br Dent J 2009: 207: 471-475.
108. Warnakulasuriya S. Food, nutrition and oral cancer. In: Wilson M editor. Food constituents and oral health. Cambridge: Woodhead Publishing Ltd, 2009: 273-295.
109. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia. J Oral Pathol Med 2008: 37: 127-133.
110. Warnakulasuriya S, Johnson NW, Van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007: 36: 575-580.
111. Warnakulasuriya S, Nagao T. Oral cancer and precancer screening: from research to policy and practice. Globel Forum Health Res 2005: 2: 188-191.
112. Warnakulasuriya S, Sutherland G, Scully C. Tobacco, oral cancer and treatment of dependence. Oral Oncol 2005: 41: 244-260.
113. Warnakulasuriya S, Trivedy C, Peters TJ. Areca nut use: an independent risk factor for oral cancer. Br Med J 2002: 324: 799-800.
114. Warnakulasuriya S. Effectiveness of tobacco counseling in the dental office. J Dent Educ 2002: 66: 1079-1087.
115. White AR, Rampes H, Campbell JL. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev 2005: (e-publication only).
116. Winstock A. Areca nut-abuse liability, dependence and public health. Addict Biol 2002: 7: 133-138.
117. Wirth LJ, Krane JF, Li Y, Othus M, Moran AE, Dorfman DM, Norris CM, Goguen L, Posner MR, Haddard RI, Bertagnolli MM. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res 2008: 1: 312-315.
118. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition and Physical Activity and Prevention of Cancer: a Global Perspective. Washington, DC: American Institute for Cancer Research, 2007.
119. World Health Organization. Control of oral cancer in developing countries. Bull World Health Organ 1984: 62: 817-830.
120. World Health Organization. Diet, nutrition, and the prevention of chronic diseases: WHO technical report series 916. Geneva: World Health Organization, 2003.
121. Zoller JE. Zur Malignen Transformation des Epithels der Mundschleimhaut unter Chemotherapie under Chemopravention Untersuchungen zur multitrischen Karzinogenese. Berlin: Quintessenz, 1995.